May 23, 2022 02:31 PM EDTUpdated May 25, 09:10 AM
FDA+

Up­dat­ed: FDA calls for non­in­fe­ri­or­i­ty tri­als for an­tibac­te­ri­als, thanks to new drugs for re­sis­tant in­fec­tions

Paul Schloesser

Associate Editor

The FDA on Mon­day said it up­dat­ed its rec­om­men­da­tions for the clin­i­cal de­vel­op­ment of new an­tibac­te­r­i­al drugs, and thanks to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Is there room for MASH drugs in a GLP-1 world?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times